| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 38 | 2025 | 420 | 7.640 |
Why?
|
| Opioid-Related Disorders | 26 | 2024 | 193 | 6.180 |
Why?
|
| Patient Protection and Affordable Care Act | 18 | 2022 | 67 | 3.870 |
Why?
|
| Medicaid | 23 | 2022 | 238 | 3.380 |
Why?
|
| Health Care Reform | 13 | 2019 | 85 | 3.100 |
Why?
|
| United States | 98 | 2025 | 7094 | 3.080 |
Why?
|
| Health Policy | 16 | 2024 | 188 | 3.040 |
Why?
|
| Disabled Persons | 4 | 2022 | 72 | 2.970 |
Why?
|
| Analgesics, Opioid | 16 | 2024 | 451 | 2.910 |
Why?
|
| Substance Abuse Treatment Centers | 13 | 2019 | 24 | 2.730 |
Why?
|
| Insurance Coverage | 14 | 2020 | 123 | 2.270 |
Why?
|
| Public Health | 6 | 2021 | 140 | 2.220 |
Why?
|
| Intellectual Disability | 4 | 2024 | 189 | 2.160 |
Why?
|
| Politics | 7 | 2020 | 52 | 1.890 |
Why?
|
| Opiate Substitution Treatment | 8 | 2024 | 41 | 1.840 |
Why?
|
| Humans | 193 | 2025 | 89864 | 1.820 |
Why?
|
| HIV Infections | 27 | 2020 | 847 | 1.750 |
Why?
|
| Drug Overdose | 6 | 2024 | 78 | 1.720 |
Why?
|
| Buprenorphine | 9 | 2024 | 41 | 1.690 |
Why?
|
| Health Services Accessibility | 19 | 2024 | 435 | 1.680 |
Why?
|
| Police | 4 | 2022 | 24 | 1.650 |
Why?
|
| Methadone | 10 | 2024 | 46 | 1.610 |
Why?
|
| Developmental Disabilities | 2 | 2024 | 202 | 1.530 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 436 | 1.530 |
Why?
|
| Insurance, Health | 5 | 2016 | 164 | 1.480 |
Why?
|
| Crisis Intervention | 2 | 2022 | 9 | 1.460 |
Why?
|
| Substance Abuse, Intravenous | 7 | 2023 | 59 | 1.440 |
Why?
|
| Social Welfare | 8 | 2011 | 19 | 1.420 |
Why?
|
| Dentists | 9 | 2019 | 11 | 1.300 |
Why?
|
| Ambulatory Care | 9 | 2022 | 186 | 1.260 |
Why?
|
| Behavior, Addictive | 2 | 2021 | 134 | 1.200 |
Why?
|
| Policy | 4 | 2023 | 35 | 1.180 |
Why?
|
| Mental Health Services | 5 | 2013 | 59 | 1.150 |
Why?
|
| Social Stigma | 3 | 2024 | 69 | 1.150 |
Why?
|
| Harm Reduction | 4 | 2024 | 23 | 1.140 |
Why?
|
| Patient-Centered Care | 5 | 2020 | 210 | 1.110 |
Why?
|
| Social Support | 4 | 2024 | 216 | 1.100 |
Why?
|
| Medicare | 5 | 2022 | 427 | 1.090 |
Why?
|
| Mass Screening | 10 | 2020 | 645 | 1.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2017 | 7 | 1.030 |
Why?
|
| Prescription Drug Misuse | 2 | 2024 | 13 | 1.030 |
Why?
|
| Smoking Cessation | 6 | 2016 | 257 | 1.020 |
Why?
|
| Public Opinion | 2 | 2024 | 44 | 1.010 |
Why?
|
| Surveys and Questionnaires | 19 | 2024 | 2649 | 1.010 |
Why?
|
| Needle-Exchange Programs | 6 | 2023 | 18 | 1.000 |
Why?
|
| Crime | 4 | 2019 | 37 | 0.970 |
Why?
|
| Mothers | 4 | 2019 | 145 | 0.960 |
Why?
|
| Caregivers | 3 | 2023 | 167 | 0.940 |
Why?
|
| Poverty | 6 | 2021 | 183 | 0.920 |
Why?
|
| Adult | 51 | 2025 | 26784 | 0.910 |
Why?
|
| Attitude of Health Personnel | 8 | 2019 | 654 | 0.890 |
Why?
|
| Male | 63 | 2025 | 42614 | 0.830 |
Why?
|
| Female | 75 | 2025 | 46529 | 0.830 |
Why?
|
| Narcotic Antagonists | 7 | 2024 | 161 | 0.830 |
Why?
|
| Health Facilities | 1 | 2022 | 39 | 0.820 |
Why?
|
| Sudden Infant Death | 4 | 2006 | 27 | 0.810 |
Why?
|
| Mass Media | 3 | 2019 | 26 | 0.810 |
Why?
|
| Firearms | 3 | 2023 | 69 | 0.810 |
Why?
|
| Smoking | 7 | 2016 | 625 | 0.810 |
Why?
|
| Emergency Service, Hospital | 7 | 2021 | 526 | 0.810 |
Why?
|
| Heroin Dependence | 4 | 2014 | 14 | 0.800 |
Why?
|
| Influenza, Human | 2 | 2022 | 340 | 0.790 |
Why?
|
| Obesity | 5 | 2016 | 972 | 0.790 |
Why?
|
| Adolescent | 31 | 2025 | 9327 | 0.790 |
Why?
|
| Medicare Part C | 1 | 2022 | 7 | 0.790 |
Why?
|
| Hand Disinfection | 1 | 2021 | 17 | 0.780 |
Why?
|
| Chicago | 10 | 2023 | 1431 | 0.770 |
Why?
|
| Masks | 1 | 2021 | 29 | 0.760 |
Why?
|
| Social Justice | 2 | 2020 | 54 | 0.760 |
Why?
|
| Pandemics | 6 | 2024 | 778 | 0.730 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 716 | 0.720 |
Why?
|
| Mental Health | 4 | 2024 | 179 | 0.720 |
Why?
|
| Managed Care Programs | 4 | 2008 | 42 | 0.720 |
Why?
|
| Mentoring | 1 | 2021 | 32 | 0.710 |
Why?
|
| Commerce | 4 | 2019 | 31 | 0.710 |
Why?
|
| Quality of Health Care | 6 | 2014 | 387 | 0.700 |
Why?
|
| Health Equity | 1 | 2022 | 96 | 0.700 |
Why?
|
| Pregnancy Complications | 4 | 2009 | 345 | 0.680 |
Why?
|
| Child | 22 | 2024 | 7233 | 0.660 |
Why?
|
| Private Sector | 4 | 2021 | 19 | 0.660 |
Why?
|
| Public Sector | 3 | 2021 | 12 | 0.650 |
Why?
|
| Ambulances | 1 | 2019 | 17 | 0.650 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 1729 | 0.640 |
Why?
|
| Wounds, Gunshot | 1 | 2020 | 99 | 0.640 |
Why?
|
| Longitudinal Studies | 10 | 2024 | 1083 | 0.630 |
Why?
|
| Medically Uninsured | 5 | 2019 | 60 | 0.630 |
Why?
|
| Social Responsibility | 1 | 2019 | 57 | 0.630 |
Why?
|
| Child Health Services | 3 | 2011 | 49 | 0.620 |
Why?
|
| Naloxone | 4 | 2024 | 68 | 0.610 |
Why?
|
| Young Adult | 12 | 2025 | 6389 | 0.610 |
Why?
|
| Single-Payer System | 2 | 2015 | 2 | 0.610 |
Why?
|
| Continuity of Patient Care | 5 | 2017 | 172 | 0.600 |
Why?
|
| Health Care Costs | 4 | 2008 | 236 | 0.600 |
Why?
|
| Criminals | 3 | 2024 | 33 | 0.590 |
Why?
|
| State Government | 4 | 2020 | 23 | 0.580 |
Why?
|
| Public Policy | 5 | 2018 | 52 | 0.580 |
Why?
|
| Language | 1 | 2019 | 156 | 0.580 |
Why?
|
| Tobacco Use Disorder | 2 | 2016 | 115 | 0.570 |
Why?
|
| Health Status Disparities | 4 | 2020 | 191 | 0.560 |
Why?
|
| Reimbursement, Incentive | 3 | 2007 | 37 | 0.560 |
Why?
|
| Health Expenditures | 4 | 2012 | 90 | 0.550 |
Why?
|
| Fentanyl | 1 | 2017 | 71 | 0.540 |
Why?
|
| Aid to Families with Dependent Children | 3 | 2008 | 4 | 0.530 |
Why?
|
| Human Rights | 1 | 2015 | 18 | 0.510 |
Why?
|
| Dental Care | 3 | 2019 | 12 | 0.510 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 244 | 0.510 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 22 | 0.510 |
Why?
|
| Adolescent Behavior | 3 | 2008 | 109 | 0.480 |
Why?
|
| Heroin | 1 | 2014 | 11 | 0.480 |
Why?
|
| HIV-1 | 11 | 2001 | 167 | 0.480 |
Why?
|
| Violence | 2 | 2023 | 153 | 0.470 |
Why?
|
| Prevalence | 15 | 2024 | 1250 | 0.470 |
Why?
|
| Masculinity | 2 | 2024 | 16 | 0.470 |
Why?
|
| Multivariate Analysis | 9 | 2021 | 983 | 0.460 |
Why?
|
| Middle Aged | 29 | 2025 | 26103 | 0.450 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 84 | 0.440 |
Why?
|
| State Medicine | 1 | 2013 | 12 | 0.440 |
Why?
|
| Smoking Prevention | 2 | 2012 | 45 | 0.440 |
Why?
|
| Cohort Studies | 9 | 2024 | 2886 | 0.440 |
Why?
|
| Mentally Ill Persons | 1 | 2013 | 6 | 0.430 |
Why?
|
| Drug Costs | 1 | 2014 | 63 | 0.430 |
Why?
|
| Health Services Research | 5 | 2019 | 138 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 607 | 0.430 |
Why?
|
| Supreme Court Decisions | 1 | 2012 | 10 | 0.420 |
Why?
|
| Vaccination | 3 | 2022 | 278 | 0.420 |
Why?
|
| Eligibility Determination | 3 | 2022 | 36 | 0.410 |
Why?
|
| Reproductive Health Services | 1 | 2012 | 20 | 0.410 |
Why?
|
| Attitude to Health | 3 | 2023 | 222 | 0.410 |
Why?
|
| Financing, Organized | 1 | 2012 | 12 | 0.400 |
Why?
|
| Refusal to Participate | 1 | 2011 | 2 | 0.390 |
Why?
|
| Cost of Illness | 2 | 2020 | 148 | 0.390 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2024 | 260 | 0.380 |
Why?
|
| Nutrition Surveys | 3 | 2011 | 111 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 1929 | 0.380 |
Why?
|
| Medical Assistance | 1 | 2011 | 2 | 0.380 |
Why?
|
| Ownership | 2 | 2023 | 26 | 0.380 |
Why?
|
| Insurance Pools | 1 | 2011 | 1 | 0.370 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 50 | 0.370 |
Why?
|
| Financing, Personal | 1 | 2011 | 21 | 0.370 |
Why?
|
| Pregnancy | 11 | 2019 | 3040 | 0.370 |
Why?
|
| Health Services Needs and Demand | 7 | 2015 | 108 | 0.370 |
Why?
|
| Primary Health Care | 3 | 2024 | 352 | 0.360 |
Why?
|
| Personal Autonomy | 1 | 2011 | 115 | 0.360 |
Why?
|
| Primary Prevention | 1 | 2011 | 82 | 0.360 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 431 | 0.350 |
Why?
|
| Directive Counseling | 1 | 2010 | 35 | 0.340 |
Why?
|
| Infant, Newborn | 14 | 2011 | 2498 | 0.330 |
Why?
|
| Federal Government | 3 | 2021 | 29 | 0.330 |
Why?
|
| Social Work | 2 | 2007 | 20 | 0.330 |
Why?
|
| Terrorism | 1 | 2009 | 9 | 0.330 |
Why?
|
| Device Approval | 1 | 2009 | 13 | 0.330 |
Why?
|
| Aged | 14 | 2024 | 19230 | 0.330 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 38 | 0.330 |
Why?
|
| Hepatitis C | 2 | 2001 | 174 | 0.320 |
Why?
|
| Parents | 2 | 2011 | 289 | 0.320 |
Why?
|
| Infant | 17 | 2011 | 3187 | 0.320 |
Why?
|
| Risk Factors | 10 | 2024 | 5548 | 0.320 |
Why?
|
| Cost-Benefit Analysis | 9 | 2020 | 466 | 0.310 |
Why?
|
| Theft | 1 | 2008 | 12 | 0.310 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 135 | 0.310 |
Why?
|
| Homicide | 2 | 2023 | 46 | 0.310 |
Why?
|
| Methamphetamine | 1 | 2009 | 88 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2024 | 539 | 0.300 |
Why?
|
| Genomics | 1 | 2013 | 776 | 0.300 |
Why?
|
| Sociology, Medical | 1 | 2007 | 4 | 0.300 |
Why?
|
| Physician Incentive Plans | 1 | 2007 | 20 | 0.300 |
Why?
|
| Michigan | 6 | 2008 | 54 | 0.290 |
Why?
|
| Mental Disorders | 3 | 2019 | 417 | 0.290 |
Why?
|
| Health Surveys | 5 | 2010 | 240 | 0.290 |
Why?
|
| Chronic Disease | 2 | 2011 | 958 | 0.290 |
Why?
|
| Narcotics | 4 | 2010 | 71 | 0.280 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2007 | 7 | 0.280 |
Why?
|
| Interviews as Topic | 4 | 2017 | 344 | 0.280 |
Why?
|
| Illinois | 3 | 2024 | 485 | 0.280 |
Why?
|
| Marijuana Abuse | 1 | 2007 | 26 | 0.280 |
Why?
|
| Case Management | 3 | 2021 | 25 | 0.280 |
Why?
|
| State Health Plans | 3 | 2015 | 14 | 0.280 |
Why?
|
| Prisoners | 3 | 2024 | 45 | 0.270 |
Why?
|
| Financing, Government | 2 | 2019 | 24 | 0.270 |
Why?
|
| Practice Patterns, Dentists' | 2 | 2019 | 3 | 0.270 |
Why?
|
| Professional Role | 2 | 2017 | 41 | 0.260 |
Why?
|
| Asphyxia | 1 | 2006 | 11 | 0.260 |
Why?
|
| Peer Group | 2 | 2024 | 86 | 0.260 |
Why?
|
| Home Nursing | 1 | 2006 | 19 | 0.260 |
Why?
|
| Regression Analysis | 5 | 2010 | 591 | 0.250 |
Why?
|
| Program Evaluation | 6 | 2016 | 312 | 0.250 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 273 | 0.240 |
Why?
|
| Socioeconomic Factors | 5 | 2023 | 594 | 0.240 |
Why?
|
| False Positive Reactions | 3 | 2012 | 223 | 0.240 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 434 | 0.240 |
Why?
|
| Blood-Borne Pathogens | 2 | 2001 | 4 | 0.240 |
Why?
|
| Urinary Bladder Diseases | 3 | 2022 | 41 | 0.240 |
Why?
|
| Oregon | 2 | 2014 | 26 | 0.240 |
Why?
|
| Airway Obstruction | 1 | 2006 | 109 | 0.240 |
Why?
|
| Child, Preschool | 16 | 2011 | 3765 | 0.240 |
Why?
|
| Diagnosis-Related Groups | 1 | 2004 | 21 | 0.230 |
Why?
|
| Occupational Therapy | 1 | 2004 | 16 | 0.230 |
Why?
|
| Social Norms | 1 | 2024 | 14 | 0.230 |
Why?
|
| Disabled Children | 1 | 2004 | 44 | 0.230 |
Why?
|
| Naltrexone | 3 | 2022 | 137 | 0.230 |
Why?
|
| Length of Stay | 2 | 2009 | 745 | 0.230 |
Why?
|
| Health Behavior | 2 | 2021 | 185 | 0.230 |
Why?
|
| Social Desirability | 1 | 2003 | 12 | 0.220 |
Why?
|
| Pediatrics | 1 | 2007 | 359 | 0.220 |
Why?
|
| Insurance, Dental | 2 | 2014 | 3 | 0.220 |
Why?
|
| Maternal Health Services | 2 | 2004 | 16 | 0.220 |
Why?
|
| Insurance Carriers | 2 | 2014 | 6 | 0.220 |
Why?
|
| Schools | 1 | 2024 | 76 | 0.220 |
Why?
|
| Physical Therapy Modalities | 1 | 2004 | 84 | 0.220 |
Why?
|
| Dietary Services | 1 | 2002 | 2 | 0.210 |
Why?
|
| Hypertension | 3 | 2024 | 747 | 0.200 |
Why?
|
| Long-Term Care | 2 | 2018 | 61 | 0.200 |
Why?
|
| Mobile Health Units | 1 | 2002 | 11 | 0.200 |
Why?
|
| Nursing Homes | 1 | 2004 | 111 | 0.200 |
Why?
|
| Substance Abuse Detection | 1 | 2002 | 12 | 0.200 |
Why?
|
| Geography | 2 | 2021 | 227 | 0.200 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 7 | 0.200 |
Why?
|
| False Negative Reactions | 1 | 2002 | 63 | 0.200 |
Why?
|
| Referral and Consultation | 4 | 2015 | 345 | 0.200 |
Why?
|
| Posture | 1 | 2002 | 125 | 0.200 |
Why?
|
| Gambling | 1 | 2025 | 161 | 0.190 |
Why?
|
| Government Agencies | 1 | 2021 | 11 | 0.190 |
Why?
|
| Diffusion of Innovation | 2 | 2013 | 72 | 0.190 |
Why?
|
| Community Health Services | 2 | 2022 | 82 | 0.190 |
Why?
|
| Suicide | 1 | 2023 | 151 | 0.190 |
Why?
|
| Home Care Services | 1 | 2022 | 75 | 0.190 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 115 | 0.190 |
Why?
|
| Probability | 2 | 2021 | 350 | 0.190 |
Why?
|
| Attitude | 1 | 2022 | 130 | 0.190 |
Why?
|
| Resource Allocation | 2 | 2015 | 65 | 0.190 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 150 | 0.180 |
Why?
|
| Cooperative Behavior | 1 | 2022 | 179 | 0.180 |
Why?
|
| Communication | 2 | 2023 | 461 | 0.180 |
Why?
|
| Anxiety | 1 | 2023 | 310 | 0.180 |
Why?
|
| Policy Making | 1 | 2001 | 63 | 0.180 |
Why?
|
| Age Factors | 7 | 2014 | 1880 | 0.180 |
Why?
|
| Defibrillators, Implantable | 1 | 2002 | 146 | 0.180 |
Why?
|
| Costs and Cost Analysis | 2 | 2014 | 153 | 0.180 |
Why?
|
| Health Care Surveys | 4 | 2012 | 281 | 0.180 |
Why?
|
| Employment | 1 | 2000 | 53 | 0.180 |
Why?
|
| Data Collection | 4 | 2014 | 377 | 0.170 |
Why?
|
| Preferred Provider Organizations | 1 | 2000 | 1 | 0.170 |
Why?
|
| Insurance, Psychiatric | 1 | 2000 | 3 | 0.170 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2000 | 10 | 0.170 |
Why?
|
| Twins | 1 | 2000 | 65 | 0.170 |
Why?
|
| Logistic Models | 5 | 2019 | 1214 | 0.170 |
Why?
|
| Cholesterol | 1 | 2022 | 360 | 0.170 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 384 | 0.170 |
Why?
|
| Prenatal Care | 2 | 2004 | 77 | 0.170 |
Why?
|
| Infant Mortality | 3 | 2006 | 59 | 0.160 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2019 | 4 | 0.160 |
Why?
|
| Internet | 1 | 2021 | 323 | 0.160 |
Why?
|
| Infant Welfare | 1 | 1999 | 6 | 0.160 |
Why?
|
| Hospitals | 1 | 2022 | 303 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 1999 | 13 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2002 | 380 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 514 | 0.160 |
Why?
|
| Spouses | 1 | 2018 | 32 | 0.160 |
Why?
|
| Pregnancy Outcome | 1 | 2000 | 258 | 0.150 |
Why?
|
| Health Insurance Exchanges | 1 | 2017 | 2 | 0.150 |
Why?
|
| Government Programs | 1 | 2017 | 8 | 0.150 |
Why?
|
| Writing | 1 | 2018 | 29 | 0.150 |
Why?
|
| Sleep | 1 | 2002 | 455 | 0.150 |
Why?
|
| Intimate Partner Violence | 1 | 2018 | 28 | 0.150 |
Why?
|
| Health Plan Implementation | 2 | 2015 | 56 | 0.140 |
Why?
|
| Models, Econometric | 2 | 2011 | 13 | 0.140 |
Why?
|
| Information Dissemination | 1 | 2018 | 116 | 0.140 |
Why?
|
| Perception | 2 | 2017 | 179 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2000 | 599 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2016 | 34 | 0.130 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 13 | 0.130 |
Why?
|
| Alcoholism | 2 | 2009 | 180 | 0.130 |
Why?
|
| Tobacco Use | 1 | 2016 | 27 | 0.130 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2008 | 17 | 0.130 |
Why?
|
| Taxes | 1 | 2015 | 3 | 0.130 |
Why?
|
| Law Enforcement | 1 | 2015 | 10 | 0.120 |
Why?
|
| Prisons | 1 | 2015 | 12 | 0.120 |
Why?
|
| Virus Replication | 1 | 1997 | 326 | 0.120 |
Why?
|
| Short Bowel Syndrome | 1 | 2015 | 38 | 0.120 |
Why?
|
| Anti-HIV Agents | 4 | 2001 | 159 | 0.120 |
Why?
|
| Tobacco Use Cessation | 1 | 2014 | 7 | 0.120 |
Why?
|
| Health Care Rationing | 1 | 2015 | 83 | 0.120 |
Why?
|
| Adaptation, Biological | 1 | 2015 | 85 | 0.120 |
Why?
|
| Cost Control | 1 | 2014 | 45 | 0.120 |
Why?
|
| Social Class | 2 | 2007 | 137 | 0.120 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2014 | 60 | 0.110 |
Why?
|
| Health Planning | 3 | 2009 | 17 | 0.110 |
Why?
|
| Qualitative Research | 3 | 2023 | 306 | 0.100 |
Why?
|
| Sex Factors | 2 | 2014 | 1074 | 0.100 |
Why?
|
| HIV Seropositivity | 3 | 2020 | 51 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2012 | 1729 | 0.100 |
Why?
|
| Diagnosis, Oral | 1 | 2012 | 1 | 0.100 |
Why?
|
| Dental Clinics | 1 | 2012 | 3 | 0.100 |
Why?
|
| Intestines | 1 | 2015 | 416 | 0.100 |
Why?
|
| Models, Theoretical | 2 | 2008 | 493 | 0.100 |
Why?
|
| HIV Core Protein p24 | 3 | 1997 | 7 | 0.100 |
Why?
|
| Needle Sharing | 2 | 2001 | 15 | 0.100 |
Why?
|
| Community-Institutional Relations | 2 | 2015 | 29 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 64 | 0.100 |
Why?
|
| National Health Programs | 1 | 2011 | 19 | 0.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2001 | 48 | 0.090 |
Why?
|
| Economic Recession | 1 | 2011 | 5 | 0.090 |
Why?
|
| Social Security | 1 | 2011 | 5 | 0.090 |
Why?
|
| Social Isolation | 2 | 2018 | 67 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 1995 | 33 | 0.090 |
Why?
|
| Income | 1 | 2011 | 85 | 0.090 |
Why?
|
| Vaccines | 1 | 2011 | 84 | 0.090 |
Why?
|
| Sex Work | 1 | 2010 | 12 | 0.090 |
Why?
|
| Birth Weight | 2 | 2001 | 148 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2011 | 8264 | 0.090 |
Why?
|
| Pneumonia, Pneumocystis | 3 | 1995 | 18 | 0.080 |
Why?
|
| Minority Groups | 1 | 2011 | 147 | 0.080 |
Why?
|
| Health Facilities, Proprietary | 1 | 2009 | 1 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2011 | 314 | 0.080 |
Why?
|
| Family Characteristics | 2 | 2006 | 49 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 2766 | 0.080 |
Why?
|
| Commitment of Mentally Ill | 1 | 2009 | 2 | 0.080 |
Why?
|
| Pulmonary Alveoli | 2 | 2001 | 71 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 168 | 0.080 |
Why?
|
| Interinstitutional Relations | 1 | 2008 | 29 | 0.080 |
Why?
|
| New York | 2 | 2006 | 73 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 156 | 0.080 |
Why?
|
| Causality | 1 | 2008 | 80 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2001 | 1497 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1054 | 0.070 |
Why?
|
| Parenting | 1 | 2008 | 69 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 222 | 0.070 |
Why?
|
| Psychotherapy | 1 | 2007 | 73 | 0.070 |
Why?
|
| Housing | 1 | 2007 | 46 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1999 | 319 | 0.070 |
Why?
|
| Hospitalization | 2 | 2022 | 886 | 0.070 |
Why?
|
| Patient Dropouts | 1 | 2006 | 30 | 0.070 |
Why?
|
| Social Control, Formal | 1 | 2006 | 12 | 0.070 |
Why?
|
| Urban Health Services | 1 | 2006 | 45 | 0.070 |
Why?
|
| Poverty Areas | 1 | 2006 | 37 | 0.070 |
Why?
|
| Infanticide | 1 | 2006 | 1 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2007 | 111 | 0.070 |
Why?
|
| Vital Statistics | 1 | 2006 | 3 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 225 | 0.070 |
Why?
|
| Narration | 1 | 2006 | 17 | 0.070 |
Why?
|
| Connecticut | 2 | 2002 | 26 | 0.060 |
Why?
|
| HIV Antibodies | 2 | 1997 | 26 | 0.060 |
Why?
|
| Maternal Welfare | 1 | 2005 | 9 | 0.060 |
Why?
|
| Women's Rights | 1 | 2005 | 7 | 0.060 |
Why?
|
| Community Mental Health Services | 1 | 2005 | 17 | 0.060 |
Why?
|
| Case Managers | 1 | 2024 | 2 | 0.060 |
Why?
|
| Women's Health Services | 1 | 2005 | 14 | 0.060 |
Why?
|
| Drug Users | 1 | 2024 | 24 | 0.060 |
Why?
|
| Cause of Death | 1 | 2006 | 269 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 160 | 0.060 |
Why?
|
| Zidovudine | 2 | 2001 | 16 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2004 | 50 | 0.060 |
Why?
|
| Healthy People Programs | 1 | 2004 | 1 | 0.060 |
Why?
|
| Health Care Coalitions | 1 | 2004 | 9 | 0.060 |
Why?
|
| Ontario | 1 | 2004 | 51 | 0.060 |
Why?
|
| Consumer Advocacy | 1 | 2004 | 10 | 0.060 |
Why?
|
| Community Health Planning | 1 | 2004 | 21 | 0.060 |
Why?
|
| Counseling | 1 | 2006 | 166 | 0.060 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2004 | 25 | 0.060 |
Why?
|
| Television | 1 | 2003 | 29 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 72 | 0.060 |
Why?
|
| Family Health | 1 | 2004 | 162 | 0.060 |
Why?
|
| Criminal Law | 1 | 2023 | 11 | 0.050 |
Why?
|
| Tobacco Industry | 1 | 2003 | 7 | 0.050 |
Why?
|
| Viral Load | 3 | 2001 | 145 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 5357 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2007 | 483 | 0.050 |
Why?
|
| Sports | 1 | 2003 | 40 | 0.050 |
Why?
|
| Air Pollution, Indoor | 1 | 2004 | 64 | 0.050 |
Why?
|
| Gender Identity | 1 | 2023 | 53 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 5 | 0.050 |
Why?
|
| Incidence | 3 | 2007 | 1600 | 0.050 |
Why?
|
| Dietetics | 1 | 2002 | 3 | 0.050 |
Why?
|
| Societies | 1 | 2002 | 16 | 0.050 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2002 | 13 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 205 | 0.050 |
Why?
|
| Age Distribution | 1 | 2023 | 199 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 1997 | 449 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2001 | 119 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2022 | 69 | 0.050 |
Why?
|
| Supine Position | 1 | 2002 | 30 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2001 | 2887 | 0.050 |
Why?
|
| Trust | 1 | 2023 | 97 | 0.050 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 177 | 0.050 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2002 | 52 | 0.050 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2001 | 5 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 848 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2002 | 221 | 0.050 |
Why?
|
| Prone Position | 1 | 2002 | 57 | 0.050 |
Why?
|
| Asbestos, Amosite | 1 | 2001 | 1 | 0.050 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2001 | 14 | 0.050 |
Why?
|
| Social Media | 1 | 2023 | 95 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2001 | 776 | 0.050 |
Why?
|
| Syringes | 1 | 2000 | 13 | 0.050 |
Why?
|
| Single Parent | 1 | 2000 | 3 | 0.050 |
Why?
|
| Community Health Centers | 1 | 2022 | 117 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2023 | 328 | 0.040 |
Why?
|
| Hospital Costs | 2 | 2011 | 109 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 128 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2001 | 155 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2000 | 92 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 3670 | 0.040 |
Why?
|
| Disease Management | 1 | 2002 | 327 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 1999 | 18 | 0.040 |
Why?
|
| Bronchi | 1 | 2001 | 230 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 1999 | 31 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 214 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 270 | 0.040 |
Why?
|
| Social Networking | 1 | 2020 | 76 | 0.040 |
Why?
|
| California | 1 | 2000 | 146 | 0.040 |
Why?
|
| Cost Allocation | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 871 | 0.040 |
Why?
|
| Algorithms | 3 | 2007 | 1908 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6779 | 0.040 |
Why?
|
| Deficiency Diseases | 2 | 1969 | 12 | 0.040 |
Why?
|
| Adolescent Health Services | 1 | 1999 | 11 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2001 | 682 | 0.040 |
Why?
|
| Self-Help Groups | 1 | 1998 | 14 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 1998 | 34 | 0.040 |
Why?
|
| Gestational Age | 1 | 2000 | 329 | 0.040 |
Why?
|
| Risk | 1 | 2000 | 657 | 0.040 |
Why?
|
| Women's Health | 1 | 1999 | 103 | 0.040 |
Why?
|
| Dentist-Patient Relations | 1 | 2017 | 3 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 166 | 0.040 |
Why?
|
| Patient Preference | 1 | 2018 | 111 | 0.040 |
Why?
|
| Ureteral Diseases | 1 | 1977 | 14 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2011 | 9185 | 0.040 |
Why?
|
| Growth Substances | 1 | 1997 | 79 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 226 | 0.040 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 304 | 0.040 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 213 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2001 | 689 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1999 | 206 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 1997 | 81 | 0.030 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 2000 | 27 | 0.030 |
Why?
|
| DNA, Viral | 2 | 1996 | 263 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1680 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 825 | 0.030 |
Why?
|
| Pneumocystis | 1 | 1995 | 4 | 0.030 |
Why?
|
| Calcinosis | 1 | 1977 | 231 | 0.030 |
Why?
|
| Antimetabolites | 1 | 2015 | 24 | 0.030 |
Why?
|
| Bromodeoxyuridine | 1 | 2015 | 58 | 0.030 |
Why?
|
| Intersectoral Collaboration | 1 | 2015 | 10 | 0.030 |
Why?
|
| Amyloidosis | 1 | 1977 | 130 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 1995 | 145 | 0.030 |
Why?
|
| DNA Damage | 1 | 1997 | 373 | 0.030 |
Why?
|
| DNA Repair | 1 | 1997 | 363 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 785 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2015 | 37 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1994 | 18 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 114 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 1995 | 919 | 0.030 |
Why?
|
| Apoptosis | 1 | 2001 | 1717 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 1998 | 1066 | 0.030 |
Why?
|
| Pneumococcal Infections | 1 | 1994 | 47 | 0.030 |
Why?
|
| Zebrafish Proteins | 1 | 2015 | 149 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 864 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2015 | 128 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 669 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 233 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2001 | 2324 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 159 | 0.030 |
Why?
|
| Angiography | 1 | 1973 | 208 | 0.030 |
Why?
|
| Stem Cells | 1 | 2015 | 376 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1993 | 120 | 0.030 |
Why?
|
| Zebrafish | 1 | 2015 | 320 | 0.030 |
Why?
|
| General Practice, Dental | 1 | 2012 | 3 | 0.030 |
Why?
|
| Evidence-Based Dentistry | 1 | 2012 | 10 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1993 | 374 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 1995 | 2018 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2000 | 1180 | 0.020 |
Why?
|
| Food Supply | 2 | 1970 | 29 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2014 | 198 | 0.020 |
Why?
|
| HIV | 1 | 2012 | 48 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 40 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2011 | 48 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 59 | 0.020 |
Why?
|
| Selection Bias | 1 | 2011 | 36 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 60 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 146 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 806 | 0.020 |
Why?
|
| Morbidity | 1 | 1970 | 149 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 744 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 302 | 0.020 |
Why?
|
| RNA, Viral | 2 | 2001 | 318 | 0.020 |
Why?
|
| Mandatory Reporting | 1 | 2008 | 7 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1669 | 0.020 |
Why?
|
| Domestic Violence | 1 | 2009 | 24 | 0.020 |
Why?
|
| Kidney | 1 | 1973 | 1148 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2392 | 0.020 |
Why?
|
| Viremia | 2 | 1999 | 49 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2009 | 98 | 0.020 |
Why?
|
| Aftercare | 1 | 2009 | 88 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 158 | 0.020 |
Why?
|
| Death Certificates | 1 | 2007 | 11 | 0.020 |
Why?
|
| Nutrition Disorders | 2 | 1970 | 15 | 0.020 |
Why?
|
| Education | 1 | 2007 | 58 | 0.020 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2006 | 2 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 27 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2009 | 284 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2007 | 161 | 0.020 |
Why?
|
| Program Development | 1 | 2006 | 127 | 0.020 |
Why?
|
| Recurrence | 1 | 2009 | 1144 | 0.020 |
Why?
|
| Iron | 2 | 2001 | 168 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 1998 | 3021 | 0.010 |
Why?
|
| Health Status | 1 | 2007 | 371 | 0.010 |
Why?
|
| Birth Certificates | 1 | 2004 | 7 | 0.010 |
Why?
|
| Leukocyte Count | 2 | 1994 | 224 | 0.010 |
Why?
|
| Mouth | 1 | 1961 | 48 | 0.010 |
Why?
|
| Instillation, Drug | 1 | 2001 | 3 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 2001 | 4 | 0.010 |
Why?
|
| Phytic Acid | 1 | 2001 | 2 | 0.010 |
Why?
|
| Sodium Benzoate | 1 | 2001 | 2 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2001 | 23 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 75 | 0.010 |
Why?
|
| Hydroxyl Radical | 1 | 2001 | 35 | 0.010 |
Why?
|
| Malnutrition | 1 | 1961 | 33 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 122 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2001 | 59 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1977 | 1607 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2001 | 162 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 199 | 0.010 |
Why?
|
| Caspases | 1 | 2001 | 155 | 0.010 |
Why?
|
| Face | 1 | 1961 | 118 | 0.010 |
Why?
|
| Prescriptions | 1 | 2000 | 23 | 0.010 |
Why?
|
| Pharmacies | 1 | 2000 | 10 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2001 | 158 | 0.010 |
Why?
|
| Animals | 2 | 2015 | 27516 | 0.010 |
Why?
|
| Receptors, Cytokine | 1 | 1999 | 28 | 0.010 |
Why?
|
| Receptors, CCR2 | 1 | 1999 | 34 | 0.010 |
Why?
|
| Perinatal Care | 1 | 1999 | 20 | 0.010 |
Why?
|
| Gene Products, nef | 1 | 1999 | 1 | 0.010 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 1999 | 1 | 0.010 |
Why?
|
| HLA-B8 Antigen | 1 | 1999 | 3 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 1999 | 52 | 0.010 |
Why?
|
| Geriatrics | 1 | 2000 | 66 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 2001 | 147 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1999 | 43 | 0.010 |
Why?
|
| Prognosis | 2 | 1998 | 3789 | 0.010 |
Why?
|
| Food Preservation | 1 | 1959 | 1 | 0.010 |
Why?
|
| Food Irradiation | 1 | 1959 | 3 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1999 | 154 | 0.010 |
Why?
|
| Hematoma | 2 | 1973 | 108 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2001 | 490 | 0.010 |
Why?
|
| Health Promotion | 1 | 2000 | 165 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1999 | 201 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 1237 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 1999 | 477 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1999 | 687 | 0.010 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 1997 | 1 | 0.010 |
Why?
|
| Dideoxynucleotides | 1 | 1997 | 1 | 0.010 |
Why?
|
| Aphidicolin | 1 | 1997 | 4 | 0.010 |
Why?
|
| Thymine Nucleotides | 1 | 1997 | 6 | 0.010 |
Why?
|
| DNA Polymerase I | 1 | 1997 | 9 | 0.010 |
Why?
|
| Cesium Radioisotopes | 1 | 1997 | 12 | 0.010 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 1997 | 7 | 0.010 |
Why?
|
| DNA Polymerase II | 1 | 1997 | 9 | 0.010 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 1997 | 10 | 0.010 |
Why?
|
| Schistosomiasis | 1 | 1977 | 5 | 0.010 |
Why?
|
| Tuberculosis, Urogenital | 1 | 1977 | 2 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1997 | 73 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1999 | 463 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1999 | 785 | 0.010 |
Why?
|
| Kidney Diseases | 2 | 1973 | 320 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1998 | 899 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 323 | 0.010 |
Why?
|
| Alleles | 1 | 1999 | 1139 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 68 | 0.010 |
Why?
|
| Bronchoalveolar Lavage | 1 | 1995 | 26 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1995 | 30 | 0.010 |
Why?
|
| DNA, Fungal | 1 | 1995 | 58 | 0.010 |
Why?
|
| Genotype | 1 | 1999 | 1853 | 0.010 |
Why?
|
| Meningitis, Pneumococcal | 1 | 1994 | 4 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 4048 | 0.010 |
Why?
|
| Disease Progression | 1 | 1998 | 1469 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 644 | 0.010 |
Why?
|
| Proteins | 2 | 1951 | 786 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1994 | 358 | 0.010 |
Why?
|
| Bacteremia | 1 | 1994 | 103 | 0.010 |
Why?
|
| Aneurysm | 1 | 1973 | 60 | 0.010 |
Why?
|
| Cell Line | 1 | 1997 | 2495 | 0.010 |
Why?
|
| Shoulder Injuries | 1 | 1972 | 17 | 0.010 |
Why?
|
| Biochemical Phenomena | 1 | 1951 | 10 | 0.010 |
Why?
|
| Riboflavin | 1 | 1951 | 7 | 0.010 |
Why?
|
| Body Fluids | 1 | 1951 | 34 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 2329 | 0.010 |
Why?
|
| DNA | 1 | 1997 | 1311 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 3024 | 0.010 |
Why?
|
| Athletic Injuries | 1 | 1972 | 97 | 0.010 |
Why?
|
| Typhoid Fever | 1 | 1970 | 4 | 0.010 |
Why?
|
| Dysentery | 1 | 1970 | 3 | 0.010 |
Why?
|
| Malaria | 1 | 1970 | 23 | 0.010 |
Why?
|
| Metabolism | 1 | 1970 | 24 | 0.010 |
Why?
|
| Survival Rate | 1 | 1994 | 1898 | 0.010 |
Why?
|
| Mutation | 1 | 2001 | 4164 | 0.010 |
Why?
|
| Avitaminosis | 1 | 1968 | 5 | 0.000 |
Why?
|
| Tuberculosis | 1 | 1970 | 121 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 1973 | 523 | 0.000 |
Why?
|
| Emaciation | 1 | 1947 | 1 | 0.000 |
Why?
|
| Anemia | 1 | 1968 | 132 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1995 | 4322 | 0.000 |
Why?
|
| Pyelonephritis | 1 | 1964 | 9 | 0.000 |
Why?
|
| Ureteral Calculi | 1 | 1964 | 10 | 0.000 |
Why?
|
| Urography | 1 | 1964 | 45 | 0.000 |
Why?
|
| Urethral Stricture | 1 | 1964 | 14 | 0.000 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1964 | 20 | 0.000 |
Why?
|
| Hydronephrosis | 1 | 1964 | 33 | 0.000 |
Why?
|
| Congenital Abnormalities | 1 | 1964 | 64 | 0.000 |
Why?
|
| Encephalitis | 1 | 1964 | 104 | 0.000 |
Why?
|
| Diverticulum | 1 | 1964 | 45 | 0.000 |
Why?
|
| Urinary Tract Infections | 1 | 1964 | 76 | 0.000 |
Why?
|
| Cerebral Angiography | 1 | 1964 | 197 | 0.000 |
Why?
|
| Cerebrovascular Disorders | 1 | 1964 | 145 | 0.000 |
Why?
|
| Brain Diseases | 1 | 1964 | 187 | 0.000 |
Why?
|
| Prostatic Hyperplasia | 1 | 1964 | 90 | 0.000 |
Why?
|
| Brain Injuries | 1 | 1964 | 166 | 0.000 |
Why?
|
| Seizures | 1 | 1964 | 308 | 0.000 |
Why?
|
| Kidney Calculi | 1 | 1964 | 343 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1961 | 497 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1964 | 783 | 0.000 |
Why?
|
| Epiphyses | 1 | 1972 | 8 | 0.000 |
Why?
|
| Elbow | 1 | 1972 | 12 | 0.000 |
Why?
|
| Humerus | 1 | 1972 | 31 | 0.000 |
Why?
|
| Shoulder | 1 | 1972 | 42 | 0.000 |
Why?
|
| Muscles | 1 | 1972 | 193 | 0.000 |
Why?
|
| Biological Transport | 1 | 1951 | 401 | 0.000 |
Why?
|
| Radiography | 1 | 1972 | 808 | 0.000 |
Why?
|